Histomolecular Profiles of Gliomas in Children and Adolescent/Young Adults (NCT04916015) | Clinical Trial Compass
CompletedNot Applicable
Histomolecular Profiles of Gliomas in Children and Adolescent/Young Adults
France128 participantsStarted 2021-04-01
Plain-language summary
In the last decades, many advances have been made in the field of genetic abnormalities of glial and glioneuronal brain tumors. In the 2016 World Health organization (WHO) Classification of Tumors of the Central Nervous System, the concept of "integrated" diagnosis emerged: histological and genetic/molecular features now define many entities. Since 2016, six updates have been published by the c-IMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy- Not Official WHO) to develop and clarify the "integrated" diagnosis. In the future WHO 2021 Classification of Tumors of the Central Nervous System, "integrated" diagnoses will take up even more importance. Even if they can have similar histological features, gliomas of children are very different from the "adult" gliomas in the molecular mechanism of oncogenesis. The histomolecular features of adolescents/young adults (AYAs) can have similarities with "pediatric-type" or "adult-type" gliomas, but few studies have focused specifically on the histomolecular profiles of gliomas in AYAs.
The investigators would like to study the cohort of patients treated for a glial and glioneuronal tumor diagnosed under the age of 25 in the Amiens University Hospital between 2008 and 2020. The investigators would like to compare the histomolecular profiles of gliomas in children (0-14 years) and AYAs (15-25 years).
Who can participate
Age range
25 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female patient
* Patient treated in the Amiens University Hospital
* Patient treated for a glial or glioneuronal brain tumor according to the 2016 WHO Classification of Tumors of the Central Nervous System ("diffuse oligodendroglia or astrocytoma tumour," "another astrocytic tumor," "another glioma" or a "mixed neuronal or glioneuronal tumour").
* Diagnosis histologically confirmed or formally established by radiologist.
* Diagnosis established between January 1, 2008 and December 31, 2020.
* No patient opposition (from adult patient, or from the holder of parental authority of the minor patient).
Exclusion Criteria:
* Uncertain diagnosis
* Patient opposition (from adult patient, or from the holder of parental authority of the minor patient).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial compared glioma tumor characteristics between children under 14 and young adults up to age 25 — based on what they found, does my child's age group tend to have a different tumor type or molecular profile, and does that affect how we should approach treatment?
2Since this study has already completed and was looking at tumor biology rather than testing a new treatment, could the findings from this research change which diagnostic tests or molecular profiling my child should have done right now?
3This trial focused on histological and molecular differences in gliomas across age groups — has my child's tumor already been tested for the kinds of molecular markers this study was examining, and if not, should we be requesting that?
4Because this was an observational study and not a treatment trial, what does my doctor think the practical takeaway is for us — does this kind of research change the standard of care options we should be considering?
5If the findings from this study show that gliomas in the 15–25 age group behave differently than those in younger children, and my child falls near one of those age boundaries, how does my doctor factor that into the treatment plan they are recommending?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Histogical glioma differences between child group(0-14 years) and AYA group (15-25 years)
Timeframe: one year
2
Molecular glioma differences between child group(0-14 years) and AYA group (15-25 years)